DARE — Dare Bioscience Share News
0.000.00%
Last trade - 00:00- $12.70m
- $5.98m
- $1.03m
Brief: Daré Bioscience Announces Positive Pharmacokinetic (Pk) Results From The Dare-Hrt1 Phase 1 / 2 Study That Support The Potential Of Dare-Hrt1 As An Effective Hormone Therapy For Both Vasomotor And Vaginal Symptoms Of Menopause
Brief: Dare Bioscience Inc Says On December 16, 2022 Co Received Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Dare Bioscience Announces New Development Program, DARE-PDM1
Brief: Dare Bioscience Inc Says On Dec. 1, 2022, Co Received Grant Payment Of About $4.4 Mln From Bill & Melinda Gates Foundation
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
Dare Bioscience rises as JonesTrading starts coverage with 'buy' rating
U.S. RESEARCH ROUNDUP- Chevron, Cooper Companies, Oncorus
Brief: Daré Bioscience Announces Positive Topline Results From Dare-Vva1 Phase 1/2 Clinical Study
Dare Bioscience Inc reports results for the quarter ended in September - Earnings Summary
Brief: Daré Bioscience Reports Q3 Loss Of $0.08 Per Share
Dare Bioscience Inc expected to post a loss of 12 cents a share - Earnings Preview
Dare Bioscience Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Daré Bioscience Announces Subject Screening For Mid-stage Respond Study Of Sildenafil Cream
Dare Bioscience rises on promising data from hormone therapy
Brief: Daré Bioscience Announces Positive Efficacy Results From The Dare-Hrt1 Phase 1 / 2 Study
Brief: Daré Bioscience Announces Ide Approval For A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study Of Ovaprene®
Brief: Daré Bioscience Announces Interim Analysis Of Phase 2B RESPOND Study Of Sildenafil Cream, 3.6%
Dare Bioscience Inc reports results for the quarter ended in June - Earnings Summary
Brief: Dare Bioscience Inc Posts Qtrly EPS $0.00